Moreover, IL4I1 induces expression of the inhibitory checkpoint proteins PD-1 and TIM3 on CD8+ T cells upon co-culture with patient-derived tumor organoids (Figure 13) (407), suggesting that IL4I1 inhibitors may need to be combined with immune checkpoint blockade for effective cancer treatment. This evidence concerns the gene CD8A and cancer.